Merus NV is a clinical-stage biotechnology company headquartered in Utrecht, Netherlands, dedicated to advancing immuno-oncology through innovative bispecific antibody therapies. Utilizing its proprietary technology platform, Merus develops targeted treatments designed to enhance immune responses against tumors, addressing significant unmet needs in the oncology sector. With a robust pipeline of clinical candidates, the company is strategically positioned to make impactful contributions to cancer therapeutics, aiming to provide effective solutions for patients facing challenging malignancies.